Inhaled Route of Administration Expected to Possess 40% Market Share For Severe Asthma Treatment Market | FMI Study

During the forecast period 2023 to 2033, the Severe Asthma Treatment Market Demand is expected to grow at a value of 5.1% CAGR, according to Future Market Insights. By the year 2033, the global market for Severe Asthma Treatment is expected to rise up to a market valuation of US$ 36.18 Billion. Growth of the market can be attributed to emergence of biologics and other targeted therapies as they have revolutionized the treatment of severe asthma, providing hope and relief for millions of people around the world who suffer from the ailment.

The Severe Asthma Treatment Market has witnessed significant growth in recent years, driven by the increasing prevalence of severe asthma cases worldwide. Severe asthma is a chronic respiratory condition characterized by frequent and severe asthma attacks that do not respond well to standard asthma medications. It can significantly impact the quality of life and is associated with high healthcare costs. As a result, there is a growing demand for effective and targeted therapies to manage and treat severe asthma.

Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16760

One of the key drivers of the market growth is the development and availability of biologic therapies specifically designed for severe asthma. Biologics, such as monoclonal antibodies, target specific immune pathways involved in the inflammatory response of asthma. These therapies have shown promising results in reducing asthma exacerbations, improving lung function, and enhancing overall asthma control in patients with severe asthma. The market has seen the introduction of several biologics, including omalizumab, mepolizumab, reslizumab, and benralizumab, which have gained regulatory approvals and are being increasingly prescribed by healthcare professionals.

In addition to biologic therapies, there is also a focus on the development of novel small molecule drugs and inhaler devices for the treatment of severe asthma. Small molecule drugs aim to target specific molecular pathways involved in asthma inflammation, providing alternative options for patients who may not respond to biologic therapies. Inhaler devices, on the other hand, play a crucial role in drug delivery and adherence, ensuring that patients receive the correct dosage of medication. The market is witnessing advancements in inhaler technology, including smart inhalers and digital health solutions, which enable better monitoring of asthma symptoms and medication usage.

Key Takeaways from the Market Study

• Severe Asthma Treatment market is expected to register a CAGR of 5.1% in the forecast period 2023 to 2033
• Inhaled route of administration is expected to possess 40% market share for Severe Asthma Treatment market in 2023.
• North America is expected to possess 45% market share for Severe Asthma Treatment market in 2023.
• Europe Severe Asthma Treatment market size is expected to possess 39% market share in 2023.

“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst

Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions: https://www.futuremarketinsights.com/ask-question/rep-gb-16760

Competitive Landscape

Key players in the Severe Asthma Treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion

• GlaxoSmithKline most significant contributions to the treatment of severe asthma has been the development and commercialization of a biologic medication called Nucala (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody that is used to treat severe eosinophilic asthma, a type of severe asthma that is characterized by high levels of eosinophils in the blood and airways.
• Novartis’ most significant contributions to the treatment of severe asthma has been the development and commercialization of a biologic medication called Xolair (omalizumab). Xolair is an anti-IgE monoclonal antibody that is used to treat severe allergic asthma, a type of severe asthma that is triggered by allergens such as pollen, dust mites, and animal dander.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe Asthma Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Buy Now to Discover Vital Trends, Drivers, and Challenges in this Industry: https://www.futuremarketinsights.com/checkout/16760

Key Segments Profiled in the Severe Asthma Treatment Industry Survey

Drug Class:

• Reslizumab
• Benralizumab
• Anti-inflammatory

Route of Administration:

• Oral
• Inhaled
• Intravenous
• Subcutaneous

Device Type:

• Dry powder inhalers
• Metered dose inhalers
• Soft mist inhalers

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs